11:00-12:30
Assessment of cardiovascular risk and gene editing therapeutics
Beyond traditional risk factors in screening for ASCVD in primary prevention
Laurens Reeskamp, The Netherlands
Laurens Reeskamp, The Netherlands
How does SCORE2 perform in different parts of Europe and in different sub-groups?
Emanuele Di Angelantonio, UK
Emanuele Di Angelantonio, UK
15:45-17:15
Cellular interplay in vascular frailty
Extracellular matrix in atherosclerosis
Thorsten Kessler, Germany
Thorsten Kessler, Germany
Fibroblast diversity in atherosclerosis
Judith Sluimer, The Netherlands
Judith Sluimer, The Netherlands
12:45-13:30
CONTROVERSY - Dealing with inflammation in ASCVD prevention
Pros
Paul Ridker, USA
Paul Ridker, USA
Cons
Ulrich Laufs, Germany
Ulrich Laufs, Germany
15:45-17:15
Diet and Lifestyle in ASCVD prevention
What is the rationale for the dietary recommendations for fat intake?
Jacob J. Christensen, Norway
Jacob J. Christensen, Norway
Physical activity and ASCVD prevention: is there a dose response curve?
Signe Sørensen Torekov, Norway
Signe Sørensen Torekov, Norway
11:00-12:30
Dyslipidemia and steatotic liver disease
New links between atherogenic dyslipidemia and metabolic dysfunction-associated steatotic liver disease
Joel Haas, France
Joel Haas, France
New isights from Hypobetalipoproteinemia
Salvatore Petta, Italy
Salvatore Petta, Italy
15:45-17:15
Familial hypercholesterolemia - new genetic and molecular aspects
New insights in the genetics of FH
Mafalda Bourbon, Portugal
Mafalda Bourbon, Portugal
Genetics of FH: from clinical to molecular classification
Alain Carrie, France
Alain Carrie, France
15:45-17:15
Familial hypercholesterolemia (FH) from screening to management
Monogenic vs polygenic hyperchol
Jacqueline S. Dron, USA
Jacqueline S. Dron, USA
How should we screen - systematic vs. Cascade
Tomas Freiberger, Czechia
Tomas Freiberger, Czechia
11:00-12:30
From epidemiology and biology to clinical decision making
AI imaging for clinical decision support
Alexios Antonopoulos, Greece
Alexios Antonopoulos, Greece
Potential of big data to improve ASCVD prediction in women
Maryam Kavousi, The Netherlands
Maryam Kavousi, The Netherlands
11:00-12:30
Immune regulation in atherosclerosis
B cells and antibody responses in atherosclerosis
Christoph Binder, Austria
Christoph Binder, Austria
Lipid receptors shaping immune cell functions in atherosclerosis
Sabine Steffens, Germany
Sabine Steffens, Germany
15:45-17:45
Mechanisms of plaque evolution in the aging artery
The changing cellular landscape in plaque dynamics
Minna Kaikkonen- Määttä, Finland
Minna Kaikkonen- Määttä, Finland
Specific roles for PI3Ks in mechanotransduction during atherosclerosis
Muriel Laffargue, France
Muriel Laffargue, France
11:00-12:30
New insights in the regulation of Lipid/ Lipoproteins metabolism
The role of ANGPTL8 in the regulation of lipid metabolism
Robert Konrad, USA
Robert Konrad, USA
Lipoprotein lipase: How can an unstable enzyme orchestrate intravascular lipolysis?
Michael Ploug, Denmark
Michael Ploug, Denmark
11:00-12:30
New therapeutics
Connecting gut hormones and lipid metabolism
Niina Matikainen, Finland
Niina Matikainen, Finland
Bariatric surgery and lipids
Geltrude Mingrone, Italy
Geltrude Mingrone, Italy
11:00-12:30
Precision medicine and ASCVD
"Primordial" prevention
Bamba Gaye, Senegal
Bamba Gaye, Senegal
Consequences of Gender Transition on ASCVD risk: a clinical perspective
Asa Tivesten, Sweden
Asa Tivesten, Sweden
15:45-17:15
Precision medicine beyond LDL-cholesterol
Lipoprotein (a) molecular mechanisms associated with athero-thrombosis: a topic for precision medicine
Gilles Lambert, France
Gilles Lambert, France
Women and ASCVD: what is different?
Lale Tokgözoğlu, Turkey
Lale Tokgözoğlu, Turkey
